anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to application of antimicrobial peptide AWRK6 in preparing medicaments for treating septicemia. The antimicrobial peptide AWRK6 is of a secondary structure, wherein the molecular weight is 2130.5, the alpha-helix serves as a main structure, the isoelectric point is 9.60, and the instability index is minus 6.74. The peptide is capable of neutralizing lipopolysaccharide (LPS) in a dose-dependent mode in vivo and in vitro and remarkably inhibiting LPS-induced release of mouse peritoneal macrophage TNF-alpha and IL-8 (interleukin-8) in mouse whole blood. Animal experiments indicate that the AWRK6 is capable of effectively protecting liver from attack of lethal dose LPS and remarkably increasing the survival rate of endotoxemia animals, and has a good treatment effect. Safety evaluation indicates that the AWRK6 is nontoxic to mouse peritoneal macrophages, while high-dose AWRK6 does not have remarkable toxic or side effect on the mouse. Therefore, the AWRK6 can be developed into a new generation of anti-infective medicaments for treating septic shock caused by LPS.
The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated. Antagonistic action strategies during exposure to the trauma-videoclips will include (a) adopting an open posture; (b) eating a palatable snack; (c) smiling; and (d) wishing on high levels of emotional distress (e.g., "come on distress hit me with your best shot"). The participant will engage in all of the four antagonistic actions for the six exposure trials.
Subjects will have a screening visit within 6 weeks prior to the Baseline visit. At Baseline visit blood will be drawn and to establish baseline values for plasma and red blood cell (RBC) very long chain fatty acids (VLCFA; C22, C24, and C26). Subjects will receive an oral dose of 50 mcg sobetirome once daily for 14 days beginning on Day 1. Subjects will be kept in the clinic on Day 1 for 16 hours following their initial dose of sobetirome for repeat blood sampling for pharmacokinetic analysis. Subjects will return to the clinic on days 7, 15, 21 and 28 for blood collection for VLCFA measurements. On day 15, after safety assessment, subjects will receive an increased dose of 100 mcg and this dose will be continued once daily through Day 28. Subjects will continue to return to the clinic weekly for blood and urine collection and safety assessments. Subjects will return to the clinic on day 42 for an End of Study visit that will involve a final measurement of VLCFA and blood and urine safety labs to check for reversibility. Safety labs will include serum chemistry, free fatty acid profile, hematology, urinalysis, and thyroid function. Subjects will be monitored with ECGs, vital signs, physical exams and assessment of adverse events.
PURPOSE: A cosmetic composition containing calluses or a culture containing the calluses is provided to improve skin whitening or anti-wrinkling effect. CONSTITUTION: A cosmetic composition contains a culture containing calluses which are cultured in a medium containing useful substances for culturing or the calluses acquired from the culture as an active ingredient. The calluses are derived from Trigonotis peduncularis, Phaseolus angularis, or Sophora japonica. A method for manufacturing the cosmetic composition comprises the steps of: inducing calluses from a plant seed in the medium containing the useful substances and culturing the calluses; and producing the cosmetic composition containing the calluses or the culture containing the calluses. The useful substances are quercetin, silymarin, lipoic acid, or a mixture thereof. The plant is Trigonotis peduncularis, Phaseoli semen, or Sophora japonica. [Reference numerals] (AA) Callus obtained from Trigonotis peduncularis or a culture containing the callus (example); (BB) Callus obtained from Trigonotis peduncularis or a culture containing the callus (comparative example); (CC) Callus obtained from Phaseolus angularis or a culture containing the callus (example); (DD) Callus obtained from Phaseolus angularis or a culture containing the callus (comparative example); (EE) Callus obtained from Sophora japonica or a culture containing the callus (example); (FF) Callus obtained from Sophora japonica or a culture containing the callus (comparative example)
The study will be conducted in two parts. The first part is efficacy exploration and the second part is efficacy verification. During the course of efficacy exploration, 33 subjects will be enrolled to preliminarily evaluate the safety and efficacy of MRG002. The second part will be adjusted according to the result of the first part. 29 subjects are planned to be enrolled. Considering the dropout rate of 10%, approximately 33 subjects are planned to be enrolled. A total of 66 subjects are planned to be enrolled in efficacy exploration and verification.
The study will involve 11 visits to the study site over 19 months. Participants will need to follow specific dietary and fluid recommendations. There will be physical examinations and medical history assessments at each visit. Testing will include undergoing magnetic resonance imaging (MRI), blood and urine tests. Study participants will be compensated for their time. Detailed study procedures will be reviewed upon contact with the study team.
Matrix stiffness potently promotes the malignant phenotype in various biological contexts. Therefore, identification of gene expression to participate in mechanical force signals transduced into downstream biochemical signaling will contribute substantially to the advances in nasopharyngeal carcinoma (NPC) treatment. In the present study, we detected that cortactin (CTTN) played an indispensable role in matrix stiffness-induced cell migration, invasion, and invadopodia formation. Advances in cancer research have highlighted that dysregulated alternative splicing contributes to cancer progression as an oncogenic driver. However, whether WT-CTTN or splice variants (SV1-CTTN or SV2-CTTN) regulate matrix stiffness-induced malignant phenotype is largely unknown. We proved that alteration of WT-CTTN expression modulated matrix stiffness-induced cell migration, invasion, and invadopodia formation. Considering that splicing factors might drive cancer progression through positive feedback loops, we analyzed and showed how the splicing factor PTBP2 and TIA1 modulated the production of WT-CTTN. Moreover, we determined that high stiffness activated PTBP2 expression. Taken together, our findings showed that the PTBP2-WT-CTTN level increases upon stiffening and then promotes cell migration, invasion, and invadopodia formation in NPC.
Subjects are stimulated 3 times in a day. Each 20 minutes stimulation are separated by a period of at least 30 minutes. Before and after each stimulation, inhibition is evaluated by cognitive tests (Go Nogo test, Stroop test, Hayling test) and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
BACKGROUND: The clavipectoral fascia plane block (CPB) is a novel anesthetic management strategy proposed by Valdes-Vilches for clavicle fractures. This study aimed to investigate the distribution of the injected solution around the clavicle and the surrounding tissues.
METHODS: Twelve clavicle samples were acquired from six cadavers. CPB was conducted using a 20 mL solution comprising methylene blue and iodinated contrast agent to improve visibility of the injected substance's dispersion. Methylene blue spread was assessed through anatomical dissection across distinct planes (subcutaneous, superficial muscular, deep muscular, and periosteal layers of the clavicle) in five cadavers. For the purpose of comparing methylene blue distribution, CT scans were performed on three cadavers.
RESULTS: Methylene blue was detected in the medial, intermediate, and lateral supraclavicular nerves, as well as superficial muscles including the deltoid, trapezius, sternocleidomastoid, and pectoralis major. However, no staining was observed in the deep muscle plane, including the subclavius, pectoralis minor, and clavipectoral fascia (CPF). Anterosuperior periosteum exhibited staining in 54% of surface, while only 4% of the posteroinferior surface. CT images displayed contrast staining in anterosuperior periclavicular region, consistent with observations from sagittal sections and anatomical dissections.
CONCLUSION: The CPB effectively distributes the administered solution in the anterosuperior region of the clavicular periosteum, superficial muscular plane, and supraclavicular nerves. However, it does not affect the posteroinferior region of the clavicular periosteum or the deep muscular plane, including the CPF.
PURPOSE:To provide the subject novel compound having high affinity with benzodiazepine receptors and an antagonistic action against chemical convulsion- inducing agents, substantially not affecting somatic functions and useful as an amnesia drug, etc. CONSTITUTION:A compound of formula I [R<1>, R<2> are H, halogen, nitro, etc.; Ar is (hetero)aryl (non)substituted with alkyl, etc.; n is 1,2; the ring A is (N- substituted) pyrrole ring or furan ring], e.g. 2-(4-chlorophenyl)-4,4a, 5,6- tetrahydro-7,9-dimethylthieno[3,4-h]cinnoline-3(2H)-one. The compound is produced by reacting a compound of formula IV with a hydrazine derivative of a formula ArNHNH2 and subsequently subjecting the produced compound of formula V to a ring-closing reaction with heating and refluxing in acetic acid. The compound of formula IV is a novel compound which is produced by reacting a compound of formula VI successively with methyl iodide and with KCN and heating and refluxing the reaction product in acetic acid and concentrated sulfuric acid.
The treatment arm will receive Palmitoleic acid (POA) supplement as Provinal® 420 mg capsules with at least 90% pure POA Ethyl Ester (less than 1% palmitic acid). Participants will be asked to consume 2 Provinal® 420 mg capsules twice a day for 8 weeks.
Previous studies in our laboratories proved that the inclusion of disodium hydrogen citrate at a very low concentration (1,5 mM/L) into the PD and HD solutions of a pH 7.25-7.45, completely abolishes the well known reaction between bicarbonate and calcium-magnesium. As citrate disposed a potent chelating capability on divalent cations, calsium and magnesium reacting with citrate form water soluble complexes. Concequently, after the entry of complexes into circulation, citrate is rapidly metabolised in the liver to bicarbonate and the released calsium and magnesium regain their pure forms.In this way, we were able to produce a single amino acid-based bicarbonate solution for PD and a single bicarbonate solution for HD, the formulation of which are tabulated in tables 1 and 2. Application of such solutions is easy practical in CAPD and HD patients. PD solution could be sterilised by filtration, and also, by heat sterilization at 100 degrees C for one hour, a classical method for sterilisation of pure bicarbonate solutions.Comparing our PD and HD solutions to the standard lactate solution with 2,5 % of glucose, and the on-line prepared HD bicarbonate solution in rabbits and in human, respectively, we noted the significant supperiority of the present solutions, in terms of simplicity, convenience, acid-base control, interdialytic hemodynamic tolerance and properly of high ultrafiltration. This latter let us to expect that our PD solution would effectively treat the patients by 2 or 3 exchanges daily. Evidently, all these beneficial advantages may be attributed to good nutrition, the natural bicarbonate buffer, the normal and constant pH of solutions and the absence of glucose byproducts, AGEs and ROS, which damage the peritoneum and all cells and tissues of the organism
This study is a randomized, double-blind, cross over trial of L-arginine and L-citrulline supplementation, L-arginine supplementation alone and placebo supplementation in healthy men. The intervention period will be 8-11 weeks for each participant and a minimum of 15 individuals will be recruited and enrolled to complete the trial. Subjects will complete the experimental protocol described below over 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks. Subjects will ingest corn-starch as a placebo, L-arginine (3g/day) or L-arginine (1.5 g/day) + L-citrulline (1.5g/day). On day 7 of the supplementation period, a skeletal muscle biopsy and blood sample will be obtained from the subjects to investigate mitochondrial function and blood amino acid and nitric oxide levels. On day 10 of the supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance. These assessments will be performed to determine the effects of co-ingesting L-arginine and L-citrulline compared to L-arginine alone and placebo administration.
Custom-made foot orthoses will be applied to participants in this arm. The orthoses will consist on a 3-mm thick polypropylene layer from heel to just proximal to the metatarsal heads, and a cover layer of polyethylene foam from heel to toe tips. Both materials will be adapted to the foot positive casts that will be obtained from all participants.
Hyperinsulinemic (high dose insulin) hypoglycemic clamp studies with oral administration of DHEA or placebo prior to each clamp x 2 on day 1. Day 2 hyperinsulinemic hypoglycemia. Participant randomized to either DHEA or placebo for baseline trial (arm 1) and 6 weeks treatment.
<P>PROBLEM TO BE SOLVED: To provide a pearlescent cosmetic prepared without heating to a temperature higher than a temperature condition of room temperature, and substantially free from a surfactant; and to provide a pharmaceutical composition and pearlescent concentrated composition.  <P>SOLUTION: The composition and the method are disclosed for producing the pearlized composition of an alcoholic hydrogel containing stearyl alcohol. Pearlizing effects are achieved in an alcoholic hydrogel at a low temperature by the addition to the alcoholic hydrogel of stearyl alcohol in a siloxane form as stearyl alcohol trialkylsiloxane. By incorporating the siloxane form of stearyl alcohol, which previously could be only handled at anhydrous conditions, into the hydroalcoholic gel, a stable pearlized alcoholic hydrogel having a lustrous pearlescent appearance is obtained. Preparation is accomplished without heating at above room temperature and without a pearlescent wax.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Following the rapid development of significant drug resistance of Plasmodium falciparum (Pf) to chloroquine and then sulfadoxine-pyrimethamine, artemether- lumefantrine (Coartem or AL) was adopted as first line therapy in Ethiopia in 2004. According to the current national malaria diagnosis and treatment guidelines updated in 2012, first-line treatment for uncomplicated P. falciparum infection is AL. First-line treatment for Plasmodium vivax (Pv) is chloroquine (CQ) alone in malarious areas and with primaquine in non-malarious areas at health center and hospital level. WHO recommends treatment of Pv with CQ or an artemisinin-based combination therapy (ACT) in combination with primaquine. For all clinical infection without laboratory confirmation, AL is the first-line treatment since AL is effective against both Pf and Pv. Thus, in Ethiopia, where treatment for malaria without laboratory confirmation occurs frequently, Pv is often treated with AL as the standard of care. Similarly, the recommended drug for mixed infection with Pf and Pv is AL. Now with wide-spread use of AL and CQ and with evidence that malaria laboratory testing is occurring in about half of those suspected with clinical evidence of malaria infection, the investigators propose to conduct an antimalarial efficacy study to monitor the effectiveness of these therapies in Ethiopia and to determine how efficacious these drugs remain for Pv. In addition, with high rates of relapse with P. vivax infection, the efficacy and safety of co-administering primaquine will be assessed. This information will inform future policy changes with respect to appropriate antimalarial strategies.
The preparation for topical application to the male sexual organ to overcome erectile dysfunction comprises, as active ingredients, at least one vasodilator and an aloe extract. The preparation includes adjuvants such as one or more of stearic acid, triethanolamine, silicone oil, cetyl alcohol, glycerol, acidic carboxyvinyl gelling agents, methyl cellulose, wax emulsifiers, methyl paraben and propyl paraben so as to form an aqueous cream or gel. The aloe extract is preferably prepared using an extract prepared from the plant aloe ferox which contains at least 30 per cent by weight amino acids and also includes polysaccharides. The vasodilator may comprise glyceryl trinitrate and/or isosorbide dinitrate, or combination of theophylline and ethylene diamine, or co-dergocrine mesylate (ie a combination of dihydroergocornine mesylate and dihydroergocristine mesylate with alpha- and beta- dihydroergocryptine mesylate). To assist penetration the adjuvants may include one or more of propylene glycol, isopropyl palmitate and isopropyl myristate. Preferably the preparation is substantially thixotropic and supplied in unit dosage form. The preparation is preferably manufactured by mixing the active ingredients as a finely divided solid or as a solution to form a solution or dispersion in an aqueous cream or gel composition. The aloe extract and one or more gelling agents are advantageously prepared as one batch, a soap composition is prepared as a second batch and thereafter the two batches are mixed to form a homogeneous mixture to which the vasodilator is admixed.
BACKGROUND: High gestational weight gain is associated with excess postpartum weight retention, yet excess postpartum weight retention is not an exclusion criterion for current gestational weight gain charts. We aimed to assess the impact of excluding individuals with high interpregnancy weight change (a proxy for excess postpartum weight retention) on gestational weight gain distributions.
METHODS: We included individuals with an index birth from 2008 to 2014 and a subsequent birth before 2019, in the population-based Stockholm-Gotland Perinatal Cohort. We estimated gestational weight gain (kg) at 25 and 37 weeks, using weight at first prenatal visit (<14 weeks) as the reference. We calculated high interpregnancy weight change (≥10 kg and ≥5 kg) using the difference between weight at the start of an index and subsequent pregnancy. We compared gestational weight gain distributions and percentiles (stratified by early-pregnancy body mass index) before and after excluding participants with high interpregnancy weight change.
RESULTS: Among 55,723 participants, 17% had ≥10 kg and 34% had ≥5 kg interpregnancy weight change. The third, tenth, 50th, 90th and 97th percentiles of gestational weight gain were similar (largely within 1 kg) before versus after excluding participants with high interpregnancy weight change, at both 25 and 37 weeks. For example, among normal weight participants at 37 weeks, the 50th and 97th percentiles were 14 kg and 23 kg including versus 13 kg and 23 kg excluding participants with ≥5 kg interpregnancy weight change.
CONCLUSIONS: Excluding individuals with excess postpartum weight retention from normative gestational weight gain charts may not meaningfully impact the charts' percentiles.
Frailty is a condition associated with a decline in physiological performance. Patients are categorized as healthy, pre-frail, or frail based on physiological and functional characteristics. Frailty is known to be influenced by various lifestyle factors such as socioeconomic status, psychological factors, diet, exercise, and genetic predisposition. With aging, there is an increase in cognitive and physical dysfunction, which correlates with an increase in frailty. Along with frailty, geriatric symptoms, mortality, and other negative health outcomes also increase in the elderly population. Therefore, early detection of frailty is crucial to implementing lifestyle changes aimed at improving cognitive and physical status. Various assessment scales are used to evaluate frailty, such as the Frailty Scale Version 9, Quality of Life Scale Short Form-36, and Modified 5-item frailty index (mFI-5) In the literature, the relationship between frailty and various blood tests such as beta-2 microglobulin, CRP, procalcitonin, vitamin D, IL-1, and IL-6 has been investigated (2). In our study, the investigators aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin,hemogram, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery. By identifying the relationship among these parameters, the investigators believe that modifiable factors contributing to frailty in patients at risk can be addressed through appropriate interventions.
The Covid-19 pandemic created new challenges for patients with diabetes and their treating physicians. In order to protect people from SARS-COV-2 infections, social contacts were reduced by restrictions on many areas of social life. As a side effect, these measures could have also led to changes in the self-management of patients with diabetes mellitus, such as lack of physical exercise, less healthy dietary behavior, and a reduced intensity of medical care. These possible changes may be associated with poorer control of blood glucose, cholesterol, and blood pressure. Therefore, the CoDiaM study will investigate how management and outcomes of diabetes are changing during the pandemic and identify associated factors.

The study is based on data of patients treated in three GP practices specialized on diabetes treatment in Hamburg, Germany. Data collection will include a written patient survey and extraction of clinical data from patient records. The patient's survey includes sociodemographic data and validated instruments to assess diabetes self-management (DSMQ), health literacy (HLS-EU-Q16), self-efficacy (General Self-efficacy scale) and perceived social support (F-SozU K14). Data will be analyzed by descriptive statistics and multivariable, multilevel linear and logistic regression analyses adjusted for possible confounders and random effects on the practice level.